Dr. William J. Graber IV, MD

Dr. Graber practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Graber's NPI, 1700816428, was assigned on July 5, 2006. Dr. Graber graduated from Tulane School of Medicine in 1991. Dr. Graber's Texas license number on file is K3211.

Dr. Graber's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Graber's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Graber practices. Vendor and product names are available with a free account.

Urology is Dr. Graber's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Graber is board certified in urology by the American Board of Urology. Dmand AI has Dr. Graber's licenses on file in 6 states: Texas, Florida, Idaho, Oklahoma, Montana and Louisiana.

Dmand AI lists enlarged prostate, enlarged prostate transurethral surgery (TURP), erectile dysfunction, kidney removal surgery, kidney stone disease, prostate cancer, urinary endoscopy and urinary tract infection among the conditions Dr. Graber treats.

CMS data shows 255 Medicare services from Dr. Graber across 10 procedure codes in 2024, for 262 Medicare patients. Medicare paid $28,723 for them.

CMS counts 262 Medicare patients who saw Dr. Graber in 2024. The largest group is 65 to 74, with 125 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 2.49, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Graber's median patient age at 74, with 23% women.

In 2024, Dr. Graber wrote 348 Medicare Part D claims for 160 patients. 95% of them were for generic drugs. CMS names the drug for 248 of them, across 11 drugs with 11 or more claims each, at $5,339 in total drug cost. In 2023, CMS named 272 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Graber for performance year 2024, reported as part of a group. Dr. Graber accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Graber as offering telehealth. CMS counts 11 procedures of prostate resection by Dr. Graber, more than 60% of the clinicians it reports for that procedure.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 8 papers to Dr. Graber, published from 2013 to 2023. 2017 was the busiest year, with 3. The most frequent topics are Brachytherapy, Prostatic Neoplasms and Ureter. Dr. Graber has published most often in Brachytherapy. Dr. Graber's most frequent co-authors are Steven J. Frank, MD, Usama Mahmood, MD and Thomas J. Pugh, MD.

CMS Open Payments shows 17 general payments to Dr. Graber from 7 drug and device companies from 2017 to 2025. Travel and lodging make up the largest share, 50% of the total. KARL STORZ Endoscopy-America paid the most, $847.

Dr. Graber graduated from Tulane School of Medicine in 1991.

Dr. Graber is in network with 6 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 4. Check the plan with the practice before a visit.